On May 1, Governor Kim Reynolds signed HF2668 into law, mandating all Iowa-regulated insurance plans to cover biomarker testing for covered individuals. Kristina Hamilton, the Iowa advocacy director for the Lung Association, issued a statement in support of this development.
Hamilton stated, “The Lung Association thanks the Iowa General Assembly for passing, and Governor Reynolds for signing HF2688 into law. Comprehensive biomarker testing allows doctors to identify abnormalities in a cell’s DNA, which helps healthcare providers determine the best course of treatment for patients. This is a significant advancement in technology and treatment that will now be more widely used by Iowans under HF2668."
She further highlighted the benefits of biomarker testing for lung cancer patients. "Studies show that lung cancer patients who have access to biomarker testing and are thus able to receive targeted therapy treatments have better overall health outcomes. Biomarker testing is a crucial part of their cancer care and has been incorporated into many clinical guidelines helping doctors make the best decisions for their patients’ health."
Despite its importance in cancer care, Hamilton noted that many individuals may still struggle to get coverage for these tests from their health insurance. She said, "Through this new law, many patients who should receive biomarker testing will no longer be unable to do so because of insurance coverage restrictions or high out-of-pocket costs.”
The law is set to take effect on January 1, 2025.
